A Comprehensive Monograph on Potassium Chloride (DB00761): From Physicochemical Properties to Clinical Application and Safety

Introduction and Overview

Executive Summary

Potassium chloride (KCl) is a simple metal halide salt that serves as a cornerstone medication for the treatment and prevention of hypokalemia (low blood potassium).[1] Despite its fundamental chemical nature, its profound physiological importance and narrow therapeutic index classify it as a high-risk medication requiring meticulous clinical management. As the principal intracellular cation, potassium is indispensable for numerous physiological processes, including nerve impulse transmission, muscle contraction (cardiac, skeletal, and smooth), and the maintenance of intracellular tonicity and renal function.[1] The administration of potassium chloride, while essential for correcting deficiencies, carries significant risks, most notably life-threatening hyperkalemia and severe gastrointestinal injury.[3] This report provides an exhaustive analysis of potassium chloride, synthesizing data on its chemical properties, pharmacology, clinical use, safety profile, and regulatory landscape to serve as a definitive resource for clinicians and researchers.

Scope and Objectives

This monograph covers the full spectrum of knowledge regarding potassium chloride, from its basic chemical identifiers (CAS 7447-40-7, DrugBank ID DB00761) to its complex clinical applications.[1] The objective is to provide a nuanced, integrated understanding of how its properties influence its therapeutic use and associated risks. The analysis reveals a central paradox: the drug's chemical simplicity belies its clinical complexity. This report will deconstruct this paradox by systematically connecting its physicochemical characteristics to its formulation science, its physiological role to its pharmacodynamic effects, and its pharmacokinetic profile to its stringent safety requirements.

Historical Context

With an initial U.S. Approval dating back to 1948, potassium chloride has a long and established history in medicine.[3] This history has been marked by significant pharmaceutical innovation aimed at mitigating its inherent risks. Early formulations, such as simple enteric-coated tablets, were associated with an unacceptably high frequency of small bowel lesions.[5] This led to the development of more advanced controlled-release systems, including wax-matrix tablets and micro-encapsulated pellets, which are designed to disperse the release of potassium chloride throughout the gastrointestinal tract and minimize local mucosal injury.[2] This evolution in formulation science underscores the persistent clinical challenge of safely delivering this essential but potentially caustic ion.

Physicochemical and Chemical Properties

A thorough understanding of the chemical and physical properties of potassium chloride is fundamental to appreciating its pharmaceutical formulation, routes of administration, and potential for local and systemic toxicity.

Identification and Nomenclature

Potassium chloride is a well-characterized inorganic salt with multiple identifiers used across scientific, industrial, and regulatory domains.

• Chemical Name: Potassium chloride.[7]
• IUPAC Name: potassium;chloride.[7]
• Molecular Formula: KCl or ClK.[7]
• CAS Number: 7447-40-7.[1]
• DrugBank ID: DB00761.[1]
• Other Key Identifiers:
• UNII: 660YQ98I10.[9]
• ChEBI ID: CHEBI:32588.[9]
• EC Number: 231-211-8.[9]
• Synonyms and Natural Forms: It is commonly known by various names depending on the context, including Muriate of Potash (in the fertilizer industry), Sylvite (its natural mineral form), and historical brand names like Enseal and Klotrix.[8]

Physical Description

Potassium chloride presents as an odorless, white or colorless vitreous crystalline solid or a white crystalline powder.[1] It possesses a distinct and strong saline taste, a characteristic that can affect patient compliance with liquid formulations.[2] While some sources describe it as hygroscopic (moisture-sensitive), others note it as nonhygroscopic, a discrepancy likely related to the purity and physical form of the material.[8] For pharmaceutical purposes, it should be protected from moisture.[8]

Structural and Thermodynamic Properties

The compound's stability and physical behavior are defined by its thermodynamic and structural characteristics.

• Molecular Weight: 74.55 g/mol.[7]
• Crystal Structure: It forms a face-centered cubic (FCC) crystal lattice, identical to that of sodium chloride (NaCl).[11]
• Melting Point: It melts at a high temperature, typically reported in the range of 770–776 °C (1418–1420 °F).[11]
• Boiling Point: The boiling point is 1,420 °C (2,590 °F), though it sublimes at 1500 °C.[9]
• Density: Its density is 1.984 g/cm³ at 25 °C, making it significantly denser than water.[11]

Solubility

The solubility profile of potassium chloride is a critical determinant of its pharmaceutical behavior.

• Water: It is freely and readily soluble in water.[8] This solubility is temperature-dependent, increasing from approximately 340-360 g/L at room temperature (20-25 °C) to 540 g/L in boiling water.[11]
• Other Solvents: It is practically insoluble in ethanol and ether but is slightly soluble in glycerol.[2]

The table below consolidates these key properties for easy reference.

Table 2.1: Key Physicochemical Properties of Potassium Chloride

Property	Value	Source(s)
Molecular Formula	KCl	7
Molar Mass	74.55 g/mol	7
Appearance	Odorless, white/colorless crystalline solid	1
Taste	Strong saline	2
Melting Point	770–776 °C	11
Boiling Point	1,420 °C	11
Density	1.984 g/cm³ (at 25 °C)	11
Water Solubility	340 g/L (at 20 °C)	14
Alcohol Solubility	Insoluble	2
Crystal Structure	Face-centered cubic (FCC)	11

These fundamental physicochemical characteristics directly dictate the challenges and strategies associated with the clinical use of potassium chloride. Its high water solubility, for instance, is a double-edged sword. While it allows for the preparation of liquid formulations for patients who cannot swallow pills, it also means that a high local concentration of dissolved potassium ions can form rapidly. This high concentration is osmotically active and directly irritating to biological membranes. This inherent property is the root cause of the most common adverse effects.

This leads directly to the primary challenge in oral potassium chloride delivery: mitigating gastrointestinal toxicity. The pharmaceutical industry's response has been the development of sophisticated extended-release formulations. Products like wax-matrix tablets (e.g., K-Tab) and micro-encapsulated pellets (e.g., Micro-K) are engineered specifically to "slow the release of potassium".[2] This strategy aims to prevent the formation of a high localized concentration of potassium chloride at any single point in the gastrointestinal tract, thereby reducing the risk of ulcerative and stenotic lesions.[2]

Similarly, the drug's physical properties govern the risks of intravenous administration. Because it is highly soluble, concentrated solutions are substantially hypertonic. For example, a 40 mEq/100 mL solution has a calculated osmolarity of 799 mOsmol/L, more than double the normal physiologic osmolarity of approximately 280-310 mOsmol/L.[4] Infusion of such hypertonic solutions can cause significant vein damage, pain, and phlebitis.[4] Furthermore, accidental extravasation (leakage into surrounding tissue) of concentrated potassium solutions can lead to severe tissue necrosis, requiring surgical intervention and, in extreme cases, amputation.[4] This direct link between a basic chemical property and a severe clinical risk explains the strict administration guidelines: oral forms must be taken with ample fluid and food, and intravenous forms must be diluted and infused slowly via a calibrated device into a large vein.[3]

Pharmacology and Mechanism of Action

Mechanism of Action

The mechanism of action of potassium chloride is direct and straightforward: it functions as an electrolyte replenisher.[1] It provides exogenous potassium (

K+) and chloride (Cl−) ions to the body, which are then incorporated into their respective physiological pools.[1] This supplementation directly addresses an existing or anticipated deficit, helping to restore normal intracellular and extracellular ion concentrations and correct associated metabolic disturbances.

The co-administration of chloride is a critical aspect of its mechanism, particularly in the most common causes of potassium depletion. Conditions like diuretic use or protracted vomiting lead to a concomitant loss of both potassium and chloride, resulting in a state known as hypochloremic metabolic alkalosis.[1] Replenishing potassium without also providing chloride would be insufficient to correct the underlying acid-base imbalance. Therefore, potassium chloride serves to restore both the cation and the anion necessary for normal homeostasis.

The Physiological Role of Potassium

To understand the pharmacology of potassium chloride, one must first appreciate the profound physiological importance of the potassium ion.

Principal Intracellular Cation

Potassium is the most abundant cation within body cells. The intracellular concentration is approximately 150 to 160 mEq per liter, which stands in stark contrast to the tightly regulated normal plasma concentration of just 3.5 to 5 mEq per liter.[1] This enormous concentration gradient—roughly 30:1—is established and actively maintained by the Na+/K+-ATPase pump, an enzyme present on all cell membranes that continuously pumps potassium into cells and sodium out.[1]

Maintenance of Membrane Potential and Excitability

This steep potassium gradient is the primary determinant of the resting membrane potential of excitable cells, such as nerve and muscle cells.[1] The resting potential is crucial for the ability of these cells to generate and transmit electrical signals (action potentials).

• Nerve Impulse Transmission: The repolarization phase of a nerve action potential is driven by the efflux of potassium ions out of the cell, which restores the negative resting potential and allows the nerve to be ready to fire again. Normal potassium levels are thus essential for the transmission of nerve impulses.[1]
• Muscle Contraction: The contractility of cardiac, skeletal, and smooth muscle is exquisitely sensitive to the extracellular potassium concentration because it directly affects their membrane potential and excitability. Both hypokalemia and hyperkalemia can disrupt this delicate balance, leading to muscle weakness, paralysis, or life-threatening cardiac arrhythmias.[1]

Cellular and Renal Function

Beyond its role in electrical excitability, potassium is vital for numerous fundamental cellular processes. It participates in the maintenance of intracellular tonicity, regulation of cell volume, protein synthesis, and carbohydrate utilization.[1] It is also essential for maintaining normal renal function, including the kidneys' ability to concentrate urine.[1]

Pathophysiology of Potassium Imbalance

Hypokalemia (Potassium Deficiency)

• Definition and Causes: Hypokalemia is defined as a serum potassium concentration below 3.5 mEq/L.[20] It develops whenever the rate of potassium loss from the body exceeds the rate of intake. Common causes include therapy with potassium-wasting diuretics (e.g., loop and thiazide diuretics), severe or chronic gastrointestinal losses from diarrhea or vomiting, and conditions like hyperaldosteronism.[1]
• Clinical Manifestations: Mild hypokalemia is often asymptomatic. As levels fall further (e.g., below 3.0 mEq/L), symptoms emerge, including muscle weakness, fatigue, and in advanced cases, flaccid paralysis and impaired respiratory function.[1] The cardiac effects are of greatest concern. The electrocardiogram (ECG) shows characteristic changes, including ST-segment depression, flattening of the T-wave, and the appearance of a prominent U-wave.[1] These changes reflect altered myocardial repolarization and can progress to premature ectopic beats and dangerous ventricular or supraventricular tachyarrhythmias.[20]

Hyperkalemia (Potassium Excess)

• Definition and Causes: Hyperkalemia is defined as a serum potassium concentration above 5.5 mEq/L.[21] It most often results from impaired renal excretion of potassium, a common complication of acute or chronic kidney disease. It can also be caused by administering potassium too rapidly (especially intravenously), extensive tissue breakdown (which releases intracellular potassium), or the use of medications that impair potassium excretion.[1]
• Clinical Manifestations: A particularly dangerous feature of hyperkalemia is that it is often asymptomatic until it becomes severe.[1] The most critical manifestations are cardiac. The ECG provides a direct window into the cardiotoxic effects, showing a predictable sequence of changes as potassium levels rise: tall, peaked T-waves appear first, followed by prolongation of the PR interval, loss of the P-wave, and widening of the QRS complex. If uncorrected, this can lead to ventricular fibrillation and cardiac arrest.[1]

The electrocardiogram, therefore, functions as more than just a safety monitoring tool; it is a sensitive, real-time pharmacodynamic biomarker for the systemic effects of potassium. The distinct and progressive changes seen in both hypokalemia and hyperkalemia are a direct reflection of the drug's impact on myocardial cell membrane potential. For example, the T-wave represents the electrical process of ventricular repolarization, which is highly dependent on potassium ion movement. The peaked T-waves of hyperkalemia reflect an abnormally rapid repolarization, while the flattened T-waves and prominent U-waves of hypokalemia reflect a delayed and disorganized repolarization. This makes the ECG an indispensable clinical tool, providing immediate feedback on the physiological impact of administered potassium, often more rapidly than a serum chemistry result can be obtained from the laboratory. This is why continuous ECG monitoring is recommended during the treatment of severe potassium imbalances.[3]

Pharmacokinetics

The clinical use of potassium chloride is governed by its pharmacokinetic profile, which is characterized by its status as an essential dietary ion rather than a xenobiotic compound.

Absorption

Potassium is a normal constituent of the diet and is readily absorbed from the gastrointestinal tract.[1] Under steady-state conditions, the amount of potassium absorbed is equal to the amount excreted, primarily in the urine.[1] Because potassium is an endogenous substance, traditional bioavailability studies based on serum concentration curves are not straightforward. Instead, regulatory assessments of bioavailability for different oral formulations rely on measuring the cumulative amount of potassium excreted in the urine over a set period (e.g., 24-48 hours) compared to a baseline, with oral solutions often serving as the reference standard.[24]

The formulation significantly impacts the rate of absorption. While liquid solutions provide rapid absorption, extended-release formulations are specifically designed to slow this process. Wax-matrix tablets (e.g., K-Tab) and micro-encapsulated capsules (e.g., Klor-Con Sprinkle) release potassium chloride gradually as they transit the GI tract.[2] This controlled release is a key safety feature designed to prevent the mucosal injury associated with high local concentrations of the salt. It is important for patients to know that the inert, porous wax matrix from some tablets is not absorbed and may be passed intact in the stool; this is a normal occurrence and does not signify treatment failure.[2]

Distribution

Following absorption into the bloodstream, potassium is distributed throughout the extracellular fluid. However, its primary residence is within the cells. The active transport system mediated by the Na+/K+-ATPase pump continuously moves potassium from the extracellular space into the intracellular space, against its concentration gradient.[1] This action maintains the high intracellular potassium concentration of approximately 150-160 mEq/L and the low, tightly controlled plasma concentration of 3.5-5.0 mEq/L.[1] Because over 98% of the body's potassium is intracellular, serum potassium levels are a poor indicator of total body potassium stores. It is estimated that a 1 mEq/L decrease in serum potassium corresponds to a total body deficit of 200 to 400 mEq.[20]

Metabolism

As a simple inorganic ion, potassium chloride is not subject to metabolism by the liver or any other organ system.[1] Its disposition in the body is governed entirely by the physiological processes of absorption, distribution, and excretion.

Elimination

The kidneys are the principal organ responsible for potassium excretion. Under normal conditions, approximately 80% to 90% of the daily potassium intake is eliminated in the urine.[16] The remaining 10-20% is excreted in the stool and, to a minor extent, in perspiration.[16]

A critical pharmacokinetic characteristic is the kidney's limited ability to conserve potassium. Even in states of potassium deficiency or during fasting, the kidneys continue to excrete potassium, which can lead to or exacerbate depletion.[16] This non-adaptive excretion contrasts with the kidney's highly efficient conservation of sodium.

This near-total reliance on renal excretion is the single most important factor determining the safety of potassium chloride therapy. In patients with normal renal function, the kidneys can typically handle standard therapeutic doses and even modest overdoses of oral potassium. However, in patients with impaired renal function, the ability to excrete a potassium load is diminished. This makes renal impairment the primary risk factor for the development of life-threatening hyperkalemia.[3] This fundamental pharmacokinetic principle dictates that any assessment of a patient for potassium chloride therapy must begin with an evaluation of their renal function. It also explains why the most significant drug-drug interactions involve medications that further impair the kidney's ability to excrete potassium, such as ACE inhibitors and potassium-sparing diuretics.[3] Therefore, renal function is not just a general consideration; it is the central pillar upon which the entire safety and dosing strategy for potassium chloride rests.

Clinical Indications and Investigational Uses

Approved Indications

The primary, FDA-approved indication for all pharmaceutical forms of potassium chloride is for the treatment and prophylaxis (prevention) of hypokalemia.[3] This indication often specifies that the hypokalemia may be with or without an accompanying metabolic alkalosis. The therapy is intended for patients in whom dietary management with potassium-rich foods or a reduction in the dose of a co-administered potassium-wasting diuretic has proven insufficient to maintain or restore normal serum potassium levels.[3]

Investigational and Component Therapy Uses

Beyond its primary role as a targeted therapy, potassium chloride is a ubiquitous component of electrolyte solutions used across a vast range of medical and surgical settings. Its presence in these contexts is often for supportive care—to maintain normal electrolyte balance—rather than to treat a pre-existing condition. Completed clinical trials illustrate this broad utility:

• Critical Care: A Phase 4 clinical trial (NCT00718068) has specifically evaluated the safety of continuous potassium chloride infusion for the treatment of hypokalemia in critically ill patients, highlighting its importance in this high-acuity setting.[30]
• Intraoperative Fluid Management: It is a standard component of intravenous fluids used to maintain hydration and electrolyte balance during major surgery, such as in a trial for laparoscopic bariatric surgery where fluid management is critical to prevent complications related to blood loss (NCT00905502).[31]
• Intestinal Lavage: Potassium chloride is included in polyethylene glycol-based oral solutions used for bowel preparation or intestinal lavage. One trial investigated such a solution for preventing complications in patients with hemorrhagic colitis caused by E. coli (NCT01561248), where maintaining electrolyte balance during the lavage is crucial.[32]
• Metabolic Acidosis Treatment: It has been studied as part of a combination therapy with potassium citrate for the treatment of metabolic acidosis in renal transplant patients (NCT00913796).[33]
• Cardioplegia: It is an essential ingredient in cardioplegic solutions. In this application, a high concentration of potassium is infused directly into the coronary arteries to rapidly induce diastolic cardiac arrest, providing a still and bloodless field for open-heart surgery.[1]
• Shock Management: It has been included in protocols for the treatment of shock syndrome.[34]

This demonstrates a clinical duality for potassium chloride. On one hand, it is a targeted, single-agent therapy prescribed to correct a specific electrolyte abnormality (hypokalemia), where its dose is carefully titrated against serum levels. On the other hand, it is a standard, often "background" component of complex multi-electrolyte solutions used for supportive care. This dual identity requires clinicians to maintain constant vigilance. While its role in a standard IV maintenance fluid may seem passive, the risks of potassium administration remain. A patient whose clinical status changes—for instance, by developing acute kidney injury—can quickly become hyperkalemic from a standard fluid infusion that was previously safe. The drug's role can shift from therapeutic to toxic without any change in the prescription, only a change in the patient's underlying physiology.

Dosage, Formulations, and Administration

The delivery of potassium chloride is accomplished through a diverse array of pharmaceutical formulations, each with specific dosing and administration guidelines designed to maximize efficacy while minimizing risk.

Available Formulations

The variety of available formulations reflects the clinical need to balance patient tolerance, acuity of need, and the inherent gastrointestinal and vascular irritant properties of the drug.

• Oral Extended-Release Tablets: These are solid dosage forms, often utilizing a wax-matrix system, designed to provide a slow, controlled release of potassium chloride. They are available in strengths of 8 mEq (600 mg), 10 mEq (750 mg), 15 mEq (1125 mg), and 20 mEq (1500 mg). Common brand names include K-Tab and Klor-Con.[2]
• Oral Extended-Release Capsules: These capsules contain multiple coated pellets, which disperse in the stomach and release the drug over time. They are available in 8 mEq (600 mg) and 10 mEq (750 mg) strengths. A key feature is that the capsules can be opened and the contents sprinkled on soft food for patients with difficulty swallowing. Brand names include Micro-K and Klor-Con Sprinkle.[27]
• Oral Solutions and Powders: For patients who cannot take solid forms or when more rapid absorption is desired, liquid formulations are available. These include oral solutions at 10% (1.3 mEq/mL or 20 mEq/15 mL) and 20% (2.6 mEq/mL or 40 mEq/15 mL) concentrations, as well as powders for oral solution in packets (e.g., 20 mEq per packet). These must be diluted in a suitable liquid before administration.[26]
• Intravenous (IV) Injections: For severe hypokalemia or when oral administration is not feasible, potassium chloride is given intravenously. It is supplied both in highly concentrated forms for pharmacy admixture and in pre-mixed, ready-to-use flexible bags. These pre-mixed solutions come in various concentrations (e.g., 10 mEq/100 mL, 20 mEq/100 mL, 40 mEq/100 mL) and are diluted in standard IV fluids like 0.9% Sodium Chloride or 5% Dextrose in Water.[4]

Dosing Regimens

Dosage must always be individualized based on the patient's serum potassium levels, the severity of the deficit, and their clinical condition.

• Treatment of Hypokalemia (Adults): The typical oral dose range is 40 to 100 mEq per day, administered in 2 to 5 divided doses. To minimize GI irritation, single oral doses are generally limited to 20 mEq for tablets and 40 mEq for liquid preparations. The total daily oral dose should not exceed 200 mEq.[3]
• Prophylaxis of Hypokalemia (Adults): A typical starting dose for prevention is 20 mEq per day, adjusted as needed based on serum monitoring.[3]
• Pediatric Dosing (Birth to 16 years): For treatment, the recommended initial dose is 2 to 4 mEq/kg/day in divided doses. For prophylaxis, the typical dose is 1 mEq/kg/day.[26] Single doses and total daily doses are capped to ensure safety.

Administration Guidelines

Strict adherence to administration guidelines is essential for safety.

• Oral Formulations: All oral forms should be taken with meals and a full glass of water or other liquid to reduce the risk of gastric irritation.[3] They should not be taken on an empty stomach.[3] Solid tablets and capsules must be swallowed whole and should not be crushed, chewed, or sucked, as this can cause immediate release of the drug, leading to mucosal irritation and negating the extended-release mechanism.[3] Specific formulations, such as sprinkle capsules or certain dividable tablets, are exceptions and should be administered according to manufacturer instructions.[25] Oral solutions and powders must be diluted in at least 4 ounces (120 mL) of cold water or juice before ingestion.[6]
• Intravenous Administration: IV potassium is reserved for severe hypokalemia (typically serum K+ < 2.5 mEq/L) or when the oral route is not viable.[3] It must be administered as a dilute solution via a calibrated infusion pump.[16] The rate of infusion generally should not exceed 10 mEq/hour, and the concentration in the IV fluid should not exceed 40 mEq/L to prevent cardiotoxicity and venous irritation.[20]

Clinical Monitoring

• Essential Monitoring: Serum potassium levels must be monitored regularly. For acute treatment, this may be daily or more frequently, while for prophylaxis, periodic monitoring (e.g., monthly to biannually) is sufficient.[3]
• Comprehensive Monitoring: In patients with cardiac disease, renal disease, or acidosis, a more comprehensive monitoring approach is required. This includes regular assessment of other electrolytes (magnesium, sodium, calcium, phosphate), acid-base status, renal function (BUN, creatinine), and electrocardiograms (ECGs) to detect signs of toxicity.[3]

The following table summarizes key clinical information for the major formulation types.

Table 6.1: Summary of Potassium Chloride Formulations and Key Administration/Monitoring Parameters

Formulation Type	Common Brand Names	Available Strengths	Key Administration Instructions	Critical Monitoring Parameters
Extended-Release Tablet	K-Tab, Klor-Con	8, 10, 15, 20 mEq	Swallow whole; do not crush, chew, or suck. Take with meals and a full glass of water.	Serum K+, renal function.
Extended-Release Capsule	Micro-K, Klor-Con Sprinkle	8, 10 mEq	Swallow whole or sprinkle contents on a spoonful of cool, soft food. Take with meals.	Serum K+, renal function.
Oral Solution / Powder	(Generic)	10% (20 mEq/15mL), 20% (40 mEq/15mL), 20 mEq packets	Must dilute in at least 4 oz of cold water or juice. Take with meals.	Serum K+, renal function.
Intravenous Infusion	(Generic)	Varies (e.g., 10, 20, 40 mEq per 50/100 mL)	Must be diluted. Infuse slowly via calibrated pump (≤10 mEq/hr). Concentration should not exceed 40 mEq/L.	Continuous ECG, serum K+ (frequent), renal function, infusion site.

Safety Profile: Adverse Reactions, Contraindications, and Warnings

The safety profile of potassium chloride is dominated by two major risks: systemic hyperkalemia and local gastrointestinal injury.

Adverse Reactions

• Common Adverse Reactions: The most frequently reported side effects are gastrointestinal in nature and are a direct result of mucosal irritation. These include nausea, vomiting, flatulence, abdominal pain or discomfort, and diarrhea.[3]
• Serious Adverse Reactions:
• Hyperkalemia: This is the most significant and potentially fatal systemic adverse reaction. It can manifest as nausea, muscle weakness, paresthesias (tingling sensations), and can progress to flaccid paralysis, hypotension, life-threatening cardiac arrhythmias (including ventricular fibrillation), and cardiac arrest.[4]
• Gastrointestinal Injury: Solid oral dosage forms are associated with a risk of more severe GI damage, including ulceration, stenosis (pathological narrowing of the GI tract), obstruction, perforation, and bleeding. Patients should be instructed to immediately report symptoms such as severe abdominal pain, distention, vomiting, or the passage of bloody or tarry stools.[2]
• Hypersensitivity Reactions: Although rare, allergic reactions such as skin rash, hives (urticaria), and angioedema (swelling of the face, lips, tongue, or throat) have been reported.[4]
• Intravenous Site Reactions: IV infusion can cause local adverse events, including pain, phlebitis (vein inflammation), and venous thrombosis. Accidental extravasation of the infusate into surrounding tissue can cause severe tissue damage and necrosis.[4]

Contraindications

The use of potassium chloride is strictly contraindicated in certain situations where the risk of severe hyperkalemia is unacceptably high:

• In patients with pre-existing hyperkalemia.[5]
• In patients receiving concomitant therapy with potassium-sparing diuretics, specifically amiloride and triamterene.[3] Spironolactone is also generally considered a contraindication or requires extreme caution.
• Solid oral dosage forms are contraindicated in patients with any structural or pharmacological cause for delayed gastrointestinal transit (e.g., diabetic gastroparesis, use of anticholinergic drugs), as this increases the risk of localized mucosal injury.[2]

Warnings and Precautions

Regulatory agencies provide stern warnings regarding the use of potassium chloride. While the product labels do not contain a formal, delineated "Black Box Warning," the gravity and prominence of the stated warnings function as a de facto equivalent, signaling the highest level of clinical caution. The language used—"can produce cardiac arrest," "potentially fatal hyperkalemia can develop rapidly and be asymptomatic"—is intended to alert prescribers to the drug's life-threatening risks.[5] The recall of a product due to a simple mislabeling of strength (a 20 mEq bag overwrapped as 10 mEq) underscores this high potential for harm, with the FDA notice stating that the resulting overdose could lead to "death from cardiac arrest".[38] Clinicians should therefore afford the drug the same level of caution as one with a formal boxed warning.

Key warnings include:

• Hyperkalemia: This is the paramount warning on all product labels. It stresses that hyperkalemia can be fatal, can develop quickly, and may be asymptomatic until cardiac toxicity is imminent. It mandates careful monitoring, especially in patients with any degree of renal impairment or those receiving other drugs that affect potassium excretion.[1]
• Gastrointestinal Injury: The labels for all solid oral forms carry explicit warnings about the risk of producing ulcerative and/or stenotic lesions. The prescribing information often contains a qualifying statement reserving these solid forms for patients who cannot tolerate liquid preparations due to this risk.[3]
• Intravenous Administration: Labels for IV products carry stringent warnings about the dangers of rapid or overly concentrated infusion. They emphasize the need for dilution, use of a calibrated infusion device, and in many cases, continuous ECG monitoring to prevent acute cardiotoxicity.[4]

Drug-Drug Interactions

Clinically significant drug interactions with potassium chloride primarily involve agents that increase the risk of hyperkalemia. These interactions are common and require vigilant management.

Interactions Increasing Hyperkalemia Risk

This is the most critical class of interactions, acting primarily through pharmacodynamic synergism or by impairing renal excretion of potassium.

• Potassium-Sparing Diuretics: The concomitant use of potassium chloride with diuretics like amiloride and triamterene is contraindicated due to the high probability of causing severe, life-threatening hyperkalemia.[3] Other aldosterone antagonists like spironolactone and eplerenone also carry a very high risk, and the combination should generally be avoided.[3]
• Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors: This broad class of drugs, which includes Angiotensin-Converting Enzyme (ACE) inhibitors (e.g., lisinopril, benazepril), Angiotensin II Receptor Blockers (ARBs) (e.g., losartan, candesartan), and direct renin inhibitors (aliskiren), all function by suppressing the RAAS. This leads to reduced aldosterone production, which in turn impairs the kidneys' ability to excrete potassium. Co-administration of potassium chloride with any RAAS inhibitor significantly increases the risk of hyperkalemia and necessitates close and frequent monitoring of serum potassium levels.[3]
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs (e.g., ibuprofen, naproxen, celecoxib) can cause potassium retention by reducing renal blood flow and inhibiting the synthesis of renal prostaglandins, which play a role in renin release and potassium excretion. When used with potassium chloride, particularly in patients with underlying renal dysfunction or those also on RAAS inhibitors, NSAIDs increase the risk of hyperkalemia. Close monitoring is required.[3]
• Other Potassium Sources: The risk of hyperkalemia is additive. Concomitant use of other potassium-containing medications (e.g., potassium phosphates, potassium citrate) or potassium-containing salt substitutes will increase the total potassium load and elevate the risk.[37]

Interactions Affecting Gastrointestinal Transit

• Anticholinergic Agents: Drugs with significant anticholinergic properties (e.g., certain bladder antispasmodics like oxybutynin, some older antidepressants, and GI motility inhibitors like glycopyrrolate) slow down gastrointestinal transit. This can dangerously prolong the contact time of solid oral potassium chloride dosage forms with the GI mucosa, markedly increasing the risk of local ulceration and stenosis. Therefore, solid forms of potassium chloride should be avoided in patients taking these agents.[2]

The following table provides a summary of these critical interactions.

Table 8.1: Clinically Significant Drug Interactions with Potassium Chloride

Interacting Drug / Class	Mechanism of Interaction	Potential Effect	Clinical Recommendation / Management	Source(s)
Potassium-Sparing Diuretics (Amiloride, Triamterene)	Additive effect; both increase serum potassium by blocking renal excretion.	Severe, life-threatening hyperkalemia.	Contraindicated.	3
Aldosterone Antagonists (Spironolactone, Eplerenone)	Additive effect; both increase serum potassium by blocking aldosterone action.	Severe hyperkalemia.	Avoid or Use Alternate Drug.	3
RAAS Inhibitors (ACE Inhibitors, ARBs, Aliskiren)	Inhibit aldosterone production, leading to decreased renal potassium excretion.	Hyperkalemia.	Use with caution. Monitor serum potassium closely and frequently, especially upon initiation or dose change.	3
NSAIDs	Inhibit renal prostaglandin synthesis, impairing renal potassium excretion.	Hyperkalemia, especially in patients with renal impairment or on RAAS inhibitors.	Use with caution. Monitor serum potassium closely.	3
Anticholinergic Agents	Decrease gastrointestinal motility, prolonging mucosal contact time.	Increased risk of GI ulceration, stenosis, or perforation from solid oral dosage forms.	Avoid concomitant use of solid oral potassium chloride. Consider liquid or effervescent preparations.	2
Baloxavir marboxil	Cation binding in the GI tract.	Decreased absorption and efficacy of baloxavir.	Avoid or Use Alternate Drug. Do not administer concomitantly.	37

Use in Specific Populations

The risks and benefits of potassium chloride therapy must be carefully weighed in specific patient populations who may have altered pharmacokinetics or increased susceptibility to adverse effects.

Renal Impairment

This is the most critical population to consider. Patients with any degree of renal impairment have a reduced capacity to excrete potassium, placing them at a substantially increased risk of developing hyperkalemia, even with standard doses.[3] Therapy in these patients must be initiated at the low end of the dosing range, and both serum potassium levels and renal function must be monitored frequently and diligently.[17]

Geriatric Use

Elderly patients are more likely to have an age-related decline in renal function, even if serum creatinine appears normal. Therefore, care should be taken in dose selection, often starting with lower doses. Periodic monitoring of renal function is recommended in this population to mitigate the risk of potassium accumulation.[3]

Hepatic Impairment (Cirrhosis)

Patients with cirrhosis may exhibit altered potassium handling. Published literature suggests that cirrhotic patients may experience a more pronounced rise in serum potassium after an oral load compared to individuals with normal liver function.[3] For this reason, it is recommended to initiate therapy at the low end of the dosing range in these patients.[17]

Pediatric Use

Potassium chloride is used in pediatric patients from birth to 16 years of age for both the treatment and prophylaxis of hypokalemia. Specific dosing guidelines, typically calculated on a mEq/kg basis, are available and must be followed carefully. Maximum single doses and total daily doses are clearly defined to ensure safety in this population.[26]

Pregnancy and Lactation

• Pregnancy: There are no adequate and well-controlled studies of potassium chloride use in pregnant women, and animal reproduction studies have not been conducted.[4] However, potassium is an essential ion, and supplementation that does not result in maternal hyperkalemia is not expected to cause fetal harm.[23] A special consideration during pregnancy is the potential for decreased gastrointestinal motility, which may increase the risk associated with solid oral dosage forms.[25]
• Lactation: Potassium is a normal constituent of human breast milk. The use of potassium chloride by a breastfeeding mother is generally considered acceptable, provided her serum potassium levels remain within the normal range. Supplementation is not expected to significantly alter the potassium concentration in breast milk.[25] As with any medication during pregnancy or lactation, use should be under the guidance of a physician.

Commercial and Regulatory Landscape

Potassium chloride is a globally available and widely used substance, with a significant presence in the pharmaceutical, food, and agricultural sectors.

Commercial Formulations and Brand Names

Reflecting its widespread use and the long history of formulation development, potassium chloride is marketed under numerous brand names worldwide. Some of the most common brand names for prescription formulations in the U.S. include:

• K-Tab [25]
• Klor-Con (and its variants like Klor-Con M, Klor-Con Sprinkle) [25]
• K-Dur [39]
• Slow-K [39]
• Micro-K [39]
• Pokonza [35]

In 2022, potassium chloride was associated with nearly 17 million prescriptions in the United States, highlighting its extensive clinical use.[41]

Manufacturing and Supply

The supply chain for potassium chloride is vast and multi-tiered.

• Bulk Chemical Production: As a fundamental chemical, KCl is produced on a massive scale by large industrial and chemical companies. It is mined from natural deposits (as sylvite) or extracted from brines.[8] Major global suppliers like ICL and Cargill produce various grades of potassium chloride for industrial, agricultural (as muriate of potash), and food applications.[42] A large number of chemical manufacturers in China, India, and Japan also supply the raw material.[44]
• Pharmaceutical Grade Manufacturing: For pharmaceutical use, the raw KCl must meet stringent purity standards, such as those defined by the United States Pharmacopeia (USP), European Pharmacopoeia (EP/BP), or Japanese Pharmacopoeia (JP).[10] Companies like Noah Chemicals, Anish Chemicals, and Takasugi Seiyaku specialize in producing this high-purity material.[44]
• Finished Dosage Form Production: Pharmaceutical companies such as Amneal Pharmaceuticals, Par Pharmaceutical, and ICU Medical, along with numerous contract and private label manufacturers, then take the pharmaceutical-grade KCl and produce the final dosage forms (tablets, capsules, solutions, injections) for distribution to pharmacies and hospitals.[27]

Regulatory Status

• Approval History: Potassium chloride is a long-established drug, with its initial approval in the United States dating back to 1948.[3]
• Regulatory Oversight: It is heavily regulated by the U.S. Food and Drug Administration (FDA) and other international health authorities. This oversight includes approval of detailed prescribing information, stringent manufacturing standards (GMP), and active post-market surveillance. The high-risk nature of the drug is reflected in regulatory actions such as nationwide recalls for manufacturing and labeling errors that could lead to dosing mistakes and patient harm.[38]
• Non-Prescription Availability: While therapeutic formulations for treating hypokalemia are available by prescription only, potassium chloride is also used as a food additive (E number E508) and is a primary ingredient in many "salt substitute" products sold over-the-counter.[11] This creates a potential for unmonitored patient intake, which can be dangerous for individuals with renal disease or those taking medications that affect potassium levels.

Conclusion

Potassium chloride is a fundamental and indispensable medication in modern medicine. Its role in correcting potassium deficiency is critical for maintaining essential physiological functions, from nerve conduction to cardiac rhythm. However, this analysis reveals that its chemical simplicity is profoundly deceptive. The very directness of its mechanism—replenishing a vital ion—is the source of its significant clinical risk. The narrow physiological range for extracellular potassium means that small errors in dosing or administration, or failures to account for a patient's underlying renal function, can rapidly shift the balance from therapeutic benefit to life-threatening toxicity.

The evolution of its pharmaceutical formulations from simple salts to complex extended-release systems is a testament to the ongoing clinical effort to manage its potent local irritant effects. The stringent warnings from regulatory bodies, which function as a de facto black box warning, underscore the gravity of its primary systemic risk: hyperkalemia. Safe and effective use of potassium chloride demands more than just a prescription; it requires a comprehensive clinical approach rooted in a deep understanding of its pharmacology, a vigilant assessment of patient-specific factors—most notably renal function—and a meticulous approach to monitoring and patient education. Ultimately, potassium chloride exemplifies a core principle of pharmacology: even the most fundamental substances require the highest degree of clinical respect and diligence.

Works cited

1. Potassium chloride: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 1, 2025, https://go.drugbank.com/drugs/DB00761
2. K-TAB® (potassium chloride extended-release tablets, USP) - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018279s034lbl.pdf
3. K-TAB (potassium chloride) extended-release ... - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018279Orig1s037lbl.pdf
4. Highly Concentrated Potassium Chloride Injection - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019904s014lbl.pdf
5. Potassium Chloride Extended-Release Capsules - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/077419lbl.pdf
6. potassium chloride oral solution - DailyMed, accessed August 1, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7c8dd5b0-db93-430f-8bf8-0318504f744c
7. 4873 - PubChem Compound Result - NCBI, accessed August 1, 2025, https://www.ncbi.nlm.nih.gov/pccompound/4873
8. CAS 7447-40-7 Potassium chloride - Alfa Chemistry, accessed August 1, 2025, https://www.alfa-chemistry.com/product/potassium-chloride-cas-7447-40-7-282208.html
9. Potassium Chloride | KCl | CID 4873 - PubChem, accessed August 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Potassium-Chloride
10. Potassium Chloride | CAS 7447-40-7 | KCl | AMERICAN ELEMENTS ®, accessed August 1, 2025, https://www.americanelements.com/potassium-chloride-7447-40-7
11. Potassium chloride - Wikipedia, accessed August 1, 2025, https://en.wikipedia.org/wiki/Potassium_chloride
12. www.chemicalbook.com, accessed August 1, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9137176.htm#:~:text=Properties%2CUses%2CProduction-,Chemical%20Properties,water%2C%20but%20insoluble%20in%20alcohol.
13. POTASSIUM CHLORIDE - CAMEO Chemicals - NOAA, accessed August 1, 2025, https://cameochemicals.noaa.gov/chemical/20948
14. Potassium chloride | 7447-40-7 - ChemicalBook, accessed August 1, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9137176.htm
15. POTASSIUM CHLORIDE CAS N°: 7447-40-7, accessed August 1, 2025, https://hpvchemicals.oecd.org/ui/handler.axd?id=2956d0b6-b409-46f0-8e89-a769869fd00d
16. Potassium Chloride Injection Highly Concentrated - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019904s020lbl.pdf
17. Label: POTASSIUM CHLORIDE tablet, film coated, extended release - DailyMed, accessed August 1, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8000e242-fe20-4d02-8f7d-97298857cf4c
18. Metabolic Alkalosis - Endocrine and Metabolic Disorders - MSD Manual Professional Edition, accessed August 1, 2025, https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/acid-base-regulation-and-disorders/metabolic-alkalosis
19. POTASSIUM CHLORIDE Label - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206814lbl.pdf
20. Hypokalemia - Endocrine and Metabolic Disorders - Merck Manual Professional Edition, accessed August 1, 2025, https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/electrolyte-disorders/hypokalemia
21. Hyperkalemia - Endocrine and Metabolic Disorders - Merck Manual Professional Edition, accessed August 1, 2025, https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/electrolyte-disorders/hyperkalemia
22. Potassium Chloride in Sodium Chloride Injection, USP in Plastic Container VIAFLEX Plus Container - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017648s071lbl.pdf
23. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018238s046lbl.pdf
24. 208019Orig1s000 - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208019Orig1s000ClinPharmR.pdf
25. Potassium Chloride: Uses, Dosage & Side Effects - Drugs.com, accessed August 1, 2025, https://www.drugs.com/potassium_chloride.html
26. POTASSIUM CHLORIDE solution - DailyMed, accessed August 1, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=25c2b417-eeea-4ba6-8eb9-a7d8a08c6093
27. Label: POTASSIUM CHLORIDE capsule, extended release - DailyMed, accessed August 1, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd56e147-92d6-46ce-ae00-63fac08d49b5
28. Label: POTASSIUM CHLORIDE solution - DailyMed, accessed August 1, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e5214432-3517-4a90-9412-036752bd1139
29. Label: POTASSIUM CHLORIDE capsule, extended release - DailyMed, accessed August 1, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=96ea00f5-b922-4d57-b2ac-34523ea56d5f
30. Hypokalemia Completed Phase 4 Trials for Potassium chloride (DB00761) - DrugBank, accessed August 1, 2025, https://go.drugbank.com/indications/DBCOND0003942/clinical_trials/DB00761?phase=4&status=completed
31. Blood Loss Completed Phase Trials for Potassium chloride (DB00761) | DrugBank Online, accessed August 1, 2025, https://go.drugbank.com/indications/DBCOND0040153/clinical_trials/DB00761?phase=&status=completed
32. Intestinal Infectious Disease Completed Phase Trials for Potassium chloride (DB00761), accessed August 1, 2025, https://go.drugbank.com/indications/DBCOND0056585/clinical_trials/DB00761?status=completed
33. Metabolic Acidosis Completed Phase 2 Trials for Potassium chloride (DB00761) - DrugBank, accessed August 1, 2025, https://go.drugbank.com/indications/DBCOND0043658/clinical_trials/DB00761?phase=2&status=completed
34. Shock syndrome Completed Phase Trials for Potassium ... - DrugBank, accessed August 1, 2025, https://go.drugbank.com/indications/DBCOND0106204/clinical_trials/DB00761?phase=&status=completed
35. Potassium chloride (Klor-Con): Uses, Side Effects, Alternatives & More - GoodRx, accessed August 1, 2025, https://www.goodrx.com/potassium-chloride/what-is
36. POTASSIUM CHLORIDE for oral solution - accessdata.fda.gov, accessed August 1, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208019s002lbl.pdf
37. Potassium chloride dosing, indications, interactions, adverse effects, and more, accessed August 1, 2025, https://reference.medscape.com/drug/kdur-slow-k-potassium-chloride-344450
38. ICU Medical Issues Nationwide Recall of Potassium Chloride Injection, 20 mEq and Potassium Chloride Injection, 10 mEq Due to Mislabeling | FDA, accessed August 1, 2025, https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/icu-medical-issues-nationwide-recall-potassium-chloride-injection-20-meq-and-potassium-chloride
39. Potassium Chloride (Klor-Con, K-Dur, and others) - Uses, Side Effects, and More - WebMD, accessed August 1, 2025, https://www.webmd.com/drugs/2/drug-676-7058/potassium-chloride-oral/potassium-extended-release-dispersible-tablet-oral/details
40. Potassium chloride - brand name list from Drugs.com, accessed August 1, 2025, https://www.drugs.com/ingredient/potassium-chloride.html
41. Potassium Chloride - Drug Usage Statistics, ClinCalc DrugStats Database, accessed August 1, 2025, https://clincalc.com/DrugStats/Drugs/PotassiumChloride
42. Potassium Chloride or Potassium Salt in Food - Cargill, accessed August 1, 2025, https://www.cargill.com/food-beverage/na/potassium-chloride-products
43. KCl Technical: Potasium Chloride For Industrial Applications, accessed August 1, 2025, https://icl-industrialproducts.com/products/potassium-chloride-industrial/
44. 17 Potassium Chloride Manufacturers in 2025 - Metoree, accessed August 1, 2025, https://us.metoree.com/categories/6601/
45. Potassium chloride manufacturers and suppliers - ChemicalBook, accessed August 1, 2025, https://m.chemicalbook.com/Manufacturers/Potassium-chloride.htm
46. Potassium Chloride/KCl/7447-40-7/High purity/Supplier | Takasugi Pharmaceutical Co., Ltd., accessed August 1, 2025, https://www.takasugi-seiyaku.co.jp/english/products/potassium_chloride_kcl_7447-40-7.html
47. Potassium Chloride Suppliers - Thomasnet, accessed August 1, 2025, https://www.thomasnet.com/suppliers/usa/potassium-chloride-62332002
48. potassium chloride, 7447-40-7 - The Good Scents Company, accessed August 1, 2025, http://www.thegoodscentscompany.com/data/rw1099551.html